These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 6240031)

  • 1. [Rush desensitization to respiratory allergens].
    Bousquet J; Guèrin B; Michel FB
    Presse Med; 1984 Dec; 13(44):2679-83. PubMed ID: 6240031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific immunotherapy in desensitization of allergic patients. Oral administration instead of injections? (interview by Andrea Warpakowski)].
    Grevers G
    MMW Fortschr Med; 2003 May; 145(18):18. PubMed ID: 12808815
    [No Abstract]   [Full Text] [Related]  

  • 4. [How great is the value of oral hyposensitization in skin test assessed allergy in comparison with parenteral treatment?].
    Luger T
    Internist (Berl); 1996 May; 37(5):519-20. PubMed ID: 9011553
    [No Abstract]   [Full Text] [Related]  

  • 5. Premedication reduces the incidence of systemic reactions during inhalant rush immunotherapy with mixtures of allergenic extracts.
    Portnoy J; Bagstad K; Kanarek H; Pacheco F; Hall B; Barnes C
    Ann Allergy; 1994 Nov; 73(5):409-18. PubMed ID: 7978533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline serum tryptase levels and adverse reactions to injection specific immunotherapy with airborne allergens: is there a relationship?
    Asero R; Farioli L; Pastorello EA
    Int Arch Allergy Immunol; 2012; 158(3):276-80. PubMed ID: 22398453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Allergen-specific immunotherapy].
    Hansen TK; Svendsen UG
    Ugeskr Laeger; 2005 Feb; 167(6):666-71. PubMed ID: 15771384
    [No Abstract]   [Full Text] [Related]  

  • 8. Double-blind placebo controlled specific immunotherapy with mixed Cupressaceae taxodiaceae pollens in respiratory allergy to Cupressus sempervirens.
    Ariano R; Panzani RC; Augeri G
    Allergol Immunopathol (Madr); 1997; 25(1):23-9. PubMed ID: 9111873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Specific desensitization].
    Vervloet D; Charpin J
    Rev Prat; 1982 Apr; 32(23):1577-8 passim. PubMed ID: 7089464
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and its persistence, in children and adults.
    Di Rienzo V
    Int J Immunopathol Pharmacol; 2005; 18(4 Suppl):35-7. PubMed ID: 17761106
    [No Abstract]   [Full Text] [Related]  

  • 11. [Sublingual vs subcutaneous immunotherapy].
    Olivé Pérez A
    Rev Alerg Mex; 2004; 51(1):29-35. PubMed ID: 15119753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
    Rossi RE; Monasterolo G; Coco G; Operti D
    Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Accelerated desensitization to lung allergens].
    Michel FB; Guerin B; Bousquet J
    Tunis Med; 1984; 62(3):201-7. PubMed ID: 6528396
    [No Abstract]   [Full Text] [Related]  

  • 14. Accelerated immunotherapy schedules: review of efficacy and safety.
    Cox L
    Ann Allergy Asthma Immunol; 2006 Aug; 97(2):126-37; quiz 137-40, 202. PubMed ID: 16937741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Allergen-specific immunotherapy (hyposensitization). Part 1. Basics and subcutaneous application].
    Klimek L
    HNO; 2000 Jan; 48(1):59-67. PubMed ID: 10663053
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety of an ultra-rush immunotherapy build-up schedule with therapeutic vaccines containing depigmented and polymerized allergen extracts.
    Casanovas M; Martín R; Jiménez C; Caballero R; Fernández-Caldas E
    Int Arch Allergy Immunol; 2006; 139(2):153-8. PubMed ID: 16374026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens. Significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment.
    Guerra F; Daza JC; Almeda E
    J Investig Allergol Clin Immunol; 2003; 13(2):108-17. PubMed ID: 12968395
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose dependence of efficacy but not of safety in sublingual immunotherapy.
    Frati F; Incorvaia C; Marcucci F; Sensi L; Di Cara G; Puccinelli P; Dal Bo S
    Monaldi Arch Chest Dis; 2006 Mar; 65(1):38-40. PubMed ID: 16700192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Practical problems in specific hyposensitization].
    Oehling A
    Med Klin; 1972 Jul; 67(29):983-8. PubMed ID: 5051382
    [No Abstract]   [Full Text] [Related]  

  • 20. [Apropos of sublingual specific immunotherapy].
    Sabbah A
    Allerg Immunol (Paris); 1998 Apr; 30(4):97-8. PubMed ID: 9631689
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.